首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1535649

大腸直腸癌治療市場規模 - 按治療（免疫療法、化療）、癌症類型（大腸直腸腺癌、胃腸道類癌）、治療提供者（醫院、專科診所）和預測，2024 - 2032 年

Colorectal Cancer Therapeutics Market Size - By Therapy (Immunotherapy, Chemotherapy), Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors), Treatment Provider (Hospitals, Specialty Clinics) & Forecast, 2024 - 2032

出版日期: 2024年06月11日 | 出版商:

Global Market Insights Inc. | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在該領域不斷增加的研發力度的推動下，2024 年至 2032 年間，全球大腸直腸癌治療市場的複合年成長率將超過 4.6%。由於大腸直腸癌仍然是全球癌症相關死亡的主要原因，因此迫切需要有效的治療方法。製藥公司和研究機構正在大力投資開發新療法，包括標靶療法、免疫療法和個人化醫療方法。

例如，2024 年 7 月，一種新型藥物組合顯示出透過非常規方法抑制腫瘤的潛力。這種策略不是抑制腫瘤細胞分裂（這是大多數標準治療的重點），而是涉及過度激活腫瘤細胞內的致癌訊號以誘導壓力。這種創新方法將在荷蘭的結直腸癌患者中進行測試。

此外，對結直腸癌遺傳和分子機制的日益了解正在為創新治療鋪平道路。政府對癌症研究的計劃和資助也在加速這些發展方面發揮著至關重要的作用。因此，在更有效、更有針對性和個性化的治療選擇的承諾的推動下，結直腸癌治療市場有望顯著成長，從而提高患者的生存率和生活品質。

整個大腸直腸癌治療產業根據治療、癌症類型、治療提供者和地區進行分類。

從治療來看，化療領域的結直腸癌治療市場佔有率從2024 年到2032 年將實現令人稱讚的複合年成長率。癌細胞的功效，仍是治療大腸直腸癌的基石。它能夠解決疾病的各個階段，特別是與其他治療方式結合使用時，確保了其持續的相關性。對有效化療方案的持續需求推動了對新藥物製劑和改進的給藥方法的需求。隨著研究的進展，將化療與新療法相結合旨在提高患者的治療效果並維持大腸癌治療的市場成長。

就癌症類型而言，從 2024 年到 2032 年，胃腸道類癌腫瘤將出現顯著成長。針對類癌獨特生物學機制的創新療法對於改善患者預後至關重要。胜肽受體放射性核素療法（PRRT）和專為神經內分泌腫瘤設計的標靶藥物的進展正在獲得關注。隨著醫療保健提供者尋求有效的解決方案來管理這些複雜的腫瘤，大腸直腸癌治療的這個利基但關鍵的領域正在推動市場成長。

2024年至2032年，歐洲大腸癌治療市場將呈現顯著的複合年成長率。該地區強大的醫療基礎設施支持創新療法的採用，包括標靶治療、免疫療法和個人化醫療。此外，研發方面的大量投資以及政府資助和監管支持正在加速新治療方案的推出。隨著歐洲國家努力改善患者的治療效果和存活率，對尖端大腸直腸癌療法的需求不斷擴大。

產業生態系統分析
產業影響力
- 成長動力
  - 大腸直腸癌的發生率和盛行率不斷增加
  - 大腸直腸癌治療的技術進步
  - 提高認知和早期發現
- 產業陷阱與挑戰
  - 與治療相關的高成本和副作用
成長潛力分析
管道分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按療法分類，2021 - 2032 年

主要趨勢
化療
免疫療法
其他療法

第 6 章：市場估計與預測：按癌症類型，2021 - 2032 年

主要趨勢
大腸直腸腺癌
胃腸道類癌
其他癌症類型

第 7 章：市場估計與預測：按治療提供者分類，2021 - 2032 年

主要趨勢
醫院
專科診所
癌症研究機構

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Amgen Inc.
Bayer AG
Bristol-Myers Squibb Company
Celleron Therapeutics
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Sumitomo Pharma Co., Ltd.
Regeneron Pharmaceuticals, Inc.
TAIHO PHARMACEUTICAL CO., LTD
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 9808

Global Colorectal Cancer Therapeutics Market will witness over 4.6% CAGR between 2024 and 2032, driven by rising research and development efforts in the field. As colorectal cancer remains a leading cause of cancer-related deaths globally, there is an urgent need for effective treatments. Pharmaceutical companies and research institutions are investing heavily in developing novel therapies, including targeted therapies, immunotherapies, and personalized medicine approaches.

For instance, in July 2024, a novel drug combination showed the potential to suppress tumors through an unconventional approach. Rather than inhibiting tumor cell division, which is the focus of most standard treatments, this strategy involved hyperactivating oncogenic signaling within the tumor cells to induce stress. This innovative approach was set to be tested in colorectal cancer patients in the Netherlands.

Additionally, the increasing understanding of the genetic and molecular mechanisms underlying colorectal cancer is paving the way for innovative treatments. Government initiatives and funding for cancer research are also playing a crucial role in accelerating these developments. As a result, the colorectal cancer therapeutics market is poised for significant growth, driven by the promise of more effective, targeted, and personalized treatment options that improve patient survival rates and quality of life.

The overall Colorectal Cancer Therapeutics Industry is classified based on the therapy, cancer type, treatment provider, and region.

Based on therapy, the colorectal cancer therapeutics market share from the chemotherapy segment will register a commendable CAGR from 2024 to 2032. Despite advancements in targeted and immunotherapy, chemotherapy remains a cornerstone in managing colorectal cancer due to its efficacy in targeting rapidly dividing cancer cells. Its ability to address various stages of the disease, especially when combined with other therapeutic modalities, ensures its ongoing relevance. The persistent need for effective chemotherapy regimens drives demand for new drug formulations and improved delivery methods. As research progresses, integrating chemotherapy with novel therapies aims to enhance patient outcomes and sustain market growth in colorectal cancer therapeutics.

In terms of cancer type, the gastrointestinal carcinoid tumors segment will witness appreciable growth from 2024 to 2032. These tumors, though rare, present unique treatment challenges that drive demand for specialized therapeutic options. Innovative therapies targeting the distinct biological mechanisms of carcinoid tumors are essential for improving patient outcomes. Advances in peptide receptor radionuclide therapy (PRRT) and targeted agents specifically designed for neuroendocrine tumors are gaining traction. This niche but critical area of colorectal cancer treatment is propelling market growth as healthcare providers seek effective solutions for managing these complex tumors.

Europe colorectal cancer therapeutics market will exhibit a notable CAGR from 2024 to 2032. Europe's aging population and increasing incidence of colorectal cancer necessitate effective treatment options, fueling market growth. The region's robust healthcare infrastructure supports the adoption of innovative therapies, including targeted treatments, immunotherapies, and personalized medicine. Additionally, significant investments in research and development, along with government funding and regulatory support, are accelerating the availability of new therapeutic options. As European countries strive to improve patient outcomes and survival rates, the demand for cutting-edge colorectal cancer therapies continues to expand.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence and prevalence of colorectal cancer
  - 3.2.1.2 Technological advancements in colorectal cancer therapeutics
  - 3.2.1.3 Increased awareness and early detection
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost and side effects associated with therapies
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Chemotherapy
5.3 Immunotherapy
5.4 Other therapies

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Colorectal adenocarcinoma
6.3 Gastrointestinal carcinoid tumors
6.4 Other cancer types

Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa